Institute for Pathology, University of Basel, Basel, Switzerland.
Int J Cancer. 2010 Dec 1;127(11):2569-75. doi: 10.1002/ijc.25265.
Confounding effects of specific KRAS gene alterations on colorectal cancer (CRC) prognosis stratified by microsatellite instability (MSI) and BRAF(V600E) have not yet been investigated. The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (Gly → Asp; G12D, Gly → Asp, G13D; Gly → Val; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients. MSI status was determined according to the Bethesda guidelines. Mutational status of KRAS and BRAF(V600E) was assessed by direct DNA sequencing. In sporadic CRC, KRAS G12D mutations had a negative prognostic effect compared to G13D and wild-type cancers (p = 0.038). With MSI, specific KRAS and BRAF(V600E) mutations, 3 distinct prognostic subgroups were observed in univariate (p = 0.006) and multivariable (p = 0.051) analysis: patients with (i) KRAS mutation G12D, G12V or BRAF(V600E) mutation, (ii) KRAS/BRAF(V600E) wild-type or KRAS G13D mutations in MSS/MSI-L and (iii) MSI-H and KRAS G13D mutations. Moreover, none of the sporadic MSI-H or hereditary patients with KRAS G13 mutations had a fatal outcome. Specific KRAS mutation is an informative prognostic factor in both sporadic and hereditary CRC and applied in an algorithm with BRAF(V600E) and MSI may identify sporadic CRC patients with poor clinical outcome.
特定 KRAS 基因突变对结直肠癌(CRC)预后的混杂影响,按微卫星不稳定性(MSI)和 BRAF(V600E)分层尚未得到研究。我们的研究目的是评估 MSI、BRAF(V600E)和特定 KRAS 突变(甘氨酸→天冬氨酸;G12D、甘氨酸→天冬氨酸、G13D;甘氨酸→缬氨酸;G12V)对 404 例散发性和 94 例遗传性 CRC 患者预后的联合影响。MSI 状态根据贝塞斯达指南确定。KRAS 和 BRAF(V600E)的突变状态通过直接 DNA 测序评估。在散发性 CRC 中,与 G13D 和野生型癌症相比,KRAS G12D 突变具有负预后作用(p=0.038)。在 MSI、特定 KRAS 和 BRAF(V600E)突变的情况下,在单变量(p=0.006)和多变量(p=0.051)分析中观察到 3 个不同的预后亚组:(i)KRAS 突变 G12D、G12V 或 BRAF(V600E)突变,(ii)KRAS/BRAF(V600E)野生型或 KRAS G13D 突变在 MSS/MSI-L 和(iii)MSI-H 和 KRAS G13D 突变。此外,没有一个散发性 MSI-H 或遗传性 KRAS G13 突变患者有致命结局。特定的 KRAS 突变是散发性和遗传性 CRC 的一个有意义的预后因素,与 BRAF(V600E)和 MSI 一起应用于算法可能会识别出预后不良的散发性 CRC 患者。